Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia

Journal of Medicinal Food

Volumn 11, Issue 2, 2008, Pages 207-214

  Zhang, Wei ^a   Wang, Xiaobing ^a   Liu, Yi ^a   Tian, Haimei ^a   Flickinger, Brent ^b   Empie, Mark W ^b   Sun, Sam Z ^b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b ARCHER DANIELS MIDLAND COMPANY   (United States)

Author keywords

Benign prostatic hyperplasia; Enterodiol; Enterolactone; Flaxseed; Lignan; Lower urinary tract symptoms; Secoisolariciresinol diglucoside

Indexed keywords

BENEFLAX; ENTERODIOL; ENTEROLACTONE; FLAXSEED EXTRACT; LIGNAN DERIVATIVE; PLACEBO; PLANT EXTRACT; SECOISOLARICIRESINOL; SECOISOLARICIRESINOL DIGLUCOSIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LINSEED; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; URINE FLOW RATE; URINE VOLUME;

AGED; AGED, 80 AND OVER; BUTYLENE GLYCOLS; DIET; DOUBLE-BLIND METHOD; FLAX; GLUCOSIDES; HUMANS; LIGNANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLACEBOS; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; URINARY TRACT; URINATION; URINE;

EID: 46749104505     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2007.602     Document Type: Article

References (64)

1. Andriole G, Bruchovsky N, Chung LW, et al.: Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172:1399-1403.
2. Tahmatzopoulos A, Kyprianou N: Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Prostate 2004;59:91-100.
3. Anglin IE, Glassman DT, Kyprianou N: Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis 2002;5:88-95.
4. Adlercreutz H: Phyto-oestrogens and cancer. Lancet Oncol 2002;3:364-373.
5. Adlercreutz H, Heinonen SM, Penalvo-Garcia J: Phytoestrogens, cancer and coronary heart disease. Biofactors 2004;22:229-236.
6. Bloedon LT, Philippe O, Szapary PO: Flaxseed and cardiovascular risk. Nutr Rev 2004;62:18-27.
7. Ghisalberti E: Cardiovascular activity of naturally occurring lignans. Phytomedicine 1997;4:151-166.
8. Stavro PM, Marchie AL, Kendall C, Vuksan V, Jenkins D: Flaxseed, fiber and coronary disease: clinical studies. In: Flaxseed in Human Nutrition (Thompson LU, Cunnane SC, eds). AOCS Press, Champaign, IL, 2003, pp. 288-300.
9. Demark-Wahnefried W, Price DT, Polascik TJ, et al.: Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology 2001;58:47-52.
10. Neven L: Lignans from flax. A solution for men's health only? Nutraceuticals Now 2003;(Summer):10-13.
11. Eliasson C, Kamal-Eldin A, Andersson R, Aman P: High-performance liquid chromatographic analysis of secoisolariciresinol diglucoside and hydroxycinnamic acid glucosides in flaxseed by alkaline extraction. J Chromatogr A 2003;1012:151-159.
12. Westcott N, Muir A, Northrup S: Analysis of flaxseed lignan after enzymatic and chemical extraction. In: Proceedings of the 57th Flax Institute of the United States. Flax Institute of the United States, Fargo, ND, 1998, pp. 27-30.
13. Evans BA, Griffiths K, Morton MS: Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 1995;147:295-302.
14. Du Y, Zhang W, Zhang M, Ding CM, Lin SB: Determination of secoisolariciresonol diglucoside, secoisolariciresonol, enterolactone and enterodiol in serum by LC/MS/MS. J Chin Mass Spectrom Soc 2006;27:168-172.
15. Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T: Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int J Urol 2006;13:15-20.
16. Desgrandchamps F, Droupy S, Irani J, Saussine C, Comenducci A: Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. BJU Int 2006;98:83-88.
17. Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T: Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 2006;97:747-751, discussion 751.
18. Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H: Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int 2005;96:581-586.
19. Zlotta AR, Teillac P, Raynaud JP, Schulman CC: Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (permixon), tamsulosin or finasteride. Eur Urol 2005;48:269-276.
20. Di Silverio F, Bosman C, Salvatori M, et al.: Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 2005;47:72-78, discussion 78-79.
21. Chung BH, Hong SJ, Lee MS: Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice. Int J Urol 2005;12:159-165.
22. Debruyne F, Boyle P, Calais Da Silva F, et al.: Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients - PERMAL study subset analysis. Eur Urol 2004;45:773-779, discussion 779-780.
23. Kirby RS, Quinn S, Mallen S, Jensen D: Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. Int J Clin Pract 2004;58:6-10.
24. Yamanishi T, Yasuda K, Kamai T, et al.: Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Int J Urol 2004;11:501-509.
25. Ikemoto I, Kiyota H, Ohishi Y, et al.: Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int J Urol 2003;10:587-594.
26. Cam K, Akman Y, Kayikci A, Senel F, Erol A: Short-term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms. Int J Urol 2003;10:582-586.
27. Sugaya K, Kadekawa K, Ikehara A, et al.: Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol 2003;10:569-574, discussion 575.
28. Kirby RS: A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003;91:41-44.
29. Debruyne F, Koch G, Boyle P, et al.: Comparison of a phytotherapeutic agent (permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002;41:497-506, discussion 506-507.
30. Sokeland J: Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int 2000;86:439-442.
31. Sanchez-Chapado M, Guil M, Badiella LI, Fernandez-Hernando N, Alfaro V: The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. BJU Int 2000;86:432-438.
32. Tsujii T: Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. Int J Urol 2000;7:199-205.
33. Guthrie RM, Siegel RL: A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). Clin Ther 1999;21:1732-1748.
34. Okada H, Kamidono S, Yoshioka T, et al.: A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int 2000;85:676-681.
35. Mimata H, Nomura Y, Kasagi Y, et al.: Prediction of alpha-blocker response in men with benign prostatic hyperplasia by magnetic resonance imaging. Urology 1999;54:829-833.
36. Chatelain C, Autet W, Brackman F: Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology 1999;54:473-478.
37. Gerber GS, Zagaja GP, Bales GT, Chodak GW, Contreras BA: Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998;51:1003-1007.
38. Nickel JC: Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. Br J Urol 1998;81:383-387.
39. Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997;80:606-611.
40. Buzelin JM, Fonteyne E, Kontturi M, Witjes WP, Khan A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol 1997;80:597-605.
41. Kurita Y, Masuda H, Suzuki K, Fujita K, Kawabe K: Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy. Br J Urol 1997;80:78-83.
42. Horvath K, Walter G, Varga A, Romics I: A novel approach to the treatment of benign prostatic hyperplasia. BJU Int 2006;97:1252-1255.
43. Nordling J: Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005;95:1006-1012.
44. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C: Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488-494, discussion 495.
45. McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398.
46. Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA: Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 2003;92:267-270.
47. Kirby RS, Roehrborn C, Boyle P, et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-126.
48. van Kerrebroeck P, Jardin A, van Cangh P, Laval KU: Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol 2002;41:54-60, discussion 60-61.
49. Preuss HG, Marcusen C, Regan J, Klimberg IW, Welebir TA, Jones WA: Randomized trial of a combination of natural products (cernitin, saw palmetto, -sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int Urol Nephrol 2001;33:217-225.
50. Kaplan SA, Holtgrewe HL, Bruskewitz R, et al.: Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001;57:1073-1077.
51. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K: A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001;87:192-200.
52. Berges RR, Kassen A, Senge T: Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int 2000;85:842-846.
53. Hudson PB, Boake R, Trachtenberg J, et al.: Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology 1999;53:690-695.
54. Marberger MJ: Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998;51:677-686.
55. Lepor H: Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998;51:901-906.
56. Lepor H: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900.
57. Denis L, Pagano F, Nonis A, Robertson C, Romano P, Boyle P: Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH. Prostate 1998;37:246-252.
58. Marks LS, Partin AW, Epstein JI, et al.: Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000;163:1451-1456.
59. Narayan P, Bruskewitz R: A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. Adv Ther 2000;17:287-300.
60. Safarinejad MR: Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 2005;5:1-11.
61. Nesbitt PD, Lam Y, Thompson LU: Human metabolism of mammalian lignan precursors in raw and processed flaxseed. Am J Clin Nutr 1999;69:549-555.
62. Morton MS, Wilcox G, Wahlqvist ML, Griffiths K: Determination of lignans and isoflavonoids in human female plasma following dietary supplementation. J Endocrinol 1994;142:251-259.
63. Kuijsten A, Arts IC, van't Veer P, Hollman PC: The relative bioavailability of enterolignans in humans is enhanced by milling and crushing of flaxseed. J Nutr 2005;135:2812-2816.
64. Sprondo RL, Collins TFX, Wiesendield PW: Effect of flaxseed consumption on male and female reproductive function and fetal development. In: Flaxseed in Human Nutrition (Thompson LU, Cunnane SC, eds). AOAC Press, Champaign, IL, 2003, pp. 341-362.